{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T04:14:23Z","timestamp":1792815263026,"version":"4.5.0"},"reference-count":245,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T00:00:00Z","timestamp":1774051200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T00:00:00Z","timestamp":1774051200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Northeastern University USA"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Deliv. and Transl. Res."],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s13346-026-02097-7","type":"journal-article","created":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T17:20:57Z","timestamp":1774113657000},"page":"2552-2577","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Formulation considerations in enhancing olfactory mucosal deposition for nose-to-brain drug delivery"],"prefix":"10.1007","volume":"16","author":[{"given":"Anisha A.","family":"DSouza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maayan","family":"Kahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Smrithi","family":"Padmakumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin S.","family":"Bleier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mansoor M.","family":"Amiji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,21]]},"reference":[{"issue":"1","key":"2097_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01481-w","volume":"8","author":"D Wu","year":"2023","unstructured":"Wu D, et al. The blood-brain barrier: structure, regulation, and drug delivery. Signal Transduct Target Ther. 2023;8(1):217.","journal-title":"Signal Transduct Target Ther"},{"key":"2097_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12102302","author":"F Wang","year":"2024","unstructured":"Wang F, et al. The mechanism and latest research progress of blood-brain barrier breakthrough. Biomedicines. 2024. https:\/\/doi.org\/10.3390\/biomedicines12102302.","journal-title":"Biomedicines"},{"issue":"6640","key":"2097_CR3","doi-asserted-by":"publisher","first-page":"eabo7649","DOI":"10.1126\/science.abo7649","volume":"380","author":"G Castellani","year":"2023","unstructured":"Castellani G, et al. Transforming the understanding of brain immunity. Science. 2023;380(6640):eabo7649.","journal-title":"Science"},{"issue":"4","key":"2097_CR4","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/S1474-4422(24)00038-3","volume":"23","author":"Collaborators, G.B.D.N.S.D.","year":"2024","unstructured":"Collaborators, G.B.D.N.S.D. Global, regional, and national burden of disorders affecting the nervous system, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet Neurol. 2024;23(4):344\u201381.","journal-title":"Lancet Neurol"},{"issue":"4","key":"2097_CR5","doi-asserted-by":"publisher","first-page":"326","DOI":"10.2174\/1570159X14666151208112754","volume":"14","author":"J Szeto","year":"2016","unstructured":"Szeto J, Lewis S. Current treatment options for Alzheimer\u2019s disease and Parkinson\u2019s disease dementia. Curr Neuropharmacol. 2016;14(4):326\u201338.","journal-title":"Curr Neuropharmacol"},{"issue":"1","key":"2097_CR6","volume":"2","author":"A Salehi","year":"2020","unstructured":"Salehi A, et al. Therapeutic enhancement of blood-brain and blood-tumor barriers permeability by laser interstitial thermal therapy. Neurooncol Adv. 2020;2(1):vdaa071.","journal-title":"Neurooncol Adv"},{"key":"2097_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14194920","author":"AM Hersh","year":"2022","unstructured":"Hersh AM, et al. Applications of focused ultrasound for the treatment of glioblastoma: a new frontier. Cancers (Basel). 2022. https:\/\/doi.org\/10.3390\/cancers14194920.","journal-title":"Cancers (Basel)"},{"issue":"7","key":"2097_CR8","first-page":"439","volume":"10","author":"J Trevino","year":"2020","unstructured":"Trevino J, et al. Non-invasive strategies for nose-to-brain drug delivery. J Clin Trials. 2020;10(7):439.","journal-title":"J Clin Trials"},{"key":"2097_CR9","doi-asserted-by":"crossref","unstructured":"Pardridge WM. Blood-brain barrier and delivery of protein and gene therapeutics to brain. frontiers in aging. Neuroscience. 2020;2019;11.","DOI":"10.3389\/fnagi.2019.00373"},{"issue":"2","key":"2097_CR10","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3109\/10717549709051878","volume":"4","author":"WH Frey","year":"1997","unstructured":"Frey WH, et al. Delivery of 125I-NGF to the brain via the olfactory route. Drug Deliv. 1997;4(2):87\u201392.","journal-title":"Drug Deliv"},{"key":"2097_CR11","unstructured":"Trevino JT et al (2020) Non-invasive strategies for nose-to-brain drug delivery. J Clin Trials 10(7)."},{"key":"2097_CR12","first-page":"479","volume-title":"K.J. Lee\u2019s essential otolaryngology","author":"KJ Lee","year":"2019","unstructured":"Lee KJ. Sinonasal development and anatomy. In: Chan Y, Goddard JC, editors. K.J. Lee\u2019s essential otolaryngology. McGraw Hill; 2019. pp. 479\u201397."},{"issue":"10","key":"2097_CR13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0162918","volume":"11","author":"R Kahana-Zweig","year":"2016","unstructured":"Kahana-Zweig R, et al. Measuring and characterizing the human nasal cycle. PLoS One. 2016;11(10):e0162918.","journal-title":"PLoS One"},{"issue":"1","key":"2097_CR14","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3233\/JAD-1998-1102","volume":"1","author":"X Chen","year":"1998","unstructured":"Chen X, et al. Delivery of nerve growth factor to the brain via the olfactory pathway. J Alzheimers Dis. 1998;1(1):35\u201344.","journal-title":"J Alzheimers Dis"},{"issue":"6","key":"2097_CR15","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1159\/000381619","volume":"61","author":"J Attems","year":"2015","unstructured":"Attems J, Walker L, Jellinger KA. Olfaction and aging: a mini-review. Gerontology. 2015;61(6):485\u201390.","journal-title":"Gerontology"},{"issue":"4","key":"2097_CR16","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.jcpa.2015.08.009","volume":"153","author":"R Chamanza","year":"2015","unstructured":"Chamanza R, Wright JA. A review of the comparative anatomy, histology, physiology and pathology of the nasal cavity of rats, mice, dogs and non-human primates. Relevance to inhalation toxicology and human health risk assessment. J Comp Pathol. 2015;153(4):287\u2013314.","journal-title":"J Comp Pathol"},{"issue":"13","key":"2097_CR17","doi-asserted-by":"publisher","first-page":"694","DOI":"10.3109\/08958378.2015.1088600","volume":"27","author":"Y Shang","year":"2015","unstructured":"Shang Y, et al. Comparative numerical modeling of inhaled micron-sized particle deposition in human and rat nasal cavities. Inhal Toxicol. 2015;27(13):694\u2013705.","journal-title":"Inhal Toxicol"},{"issue":"8","key":"2097_CR18","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1080\/17425247.2024.2392790","volume":"21","author":"C Darquenne","year":"2024","unstructured":"Darquenne C, et al. The effects of airway disease on the deposition of inhaled drugs. Expert Opin Drug Deliv. 2024;21(8):1175\u201390.","journal-title":"Expert Opin Drug Deliv"},{"issue":"4","key":"2097_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/lio2.1308","volume":"9","author":"Y Guo","year":"2024","unstructured":"Guo Y, et al. Influencing factors of particle deposition in the human nasal cavity. Laryngoscope Investig Otolaryngol. 2024;9(4):e1308.","journal-title":"Laryngoscope Investig Otolaryngol"},{"key":"2097_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmpb.2023.107778","volume":"241","author":"Z Shen","year":"2023","unstructured":"Shen Z, et al. Numerical analysis of airflow and particle deposition in multi-fidelity designs of nasal replicas following nasal administration. Comput Methods Programs Biomed. 2023;241:107778.","journal-title":"Comput Methods Programs Biomed"},{"issue":"10","key":"2097_CR21","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1002\/ar.23844","volume":"301","author":"RD Alvites","year":"2018","unstructured":"Alvites RD, et al. The Nasal Cavity of the Rat and Mouse\u2014Source of Mesenchymal Stem Cells for Treatment of Peripheral Nerve Injury. Anat Rec. 2018;301(10):1678\u201389.","journal-title":"Anat Rec"},{"issue":"Pt 1","key":"2097_CR22","first-page":"83","volume":"135","author":"EA Gross","year":"1982","unstructured":"Gross EA, et al. Comparative morphometry of the nasal cavity in rats and mice. J Anat. 1982;135(Pt 1):83\u20138.","journal-title":"J Anat"},{"issue":"2","key":"2097_CR23","doi-asserted-by":"publisher","first-page":"187","DOI":"10.5005\/jp-journals-10005-1917","volume":"14","author":"R Kalaskar","year":"2021","unstructured":"Kalaskar R, Balasubramanian S, Kalaskar A. Evaluation of the average nasal and nasopharyngeal volume in 10\u201313-year-old children: a preliminary CBCT study. Int J Clin Pediatr Dent. 2021;14(2):187\u201391.","journal-title":"Int J Clin Pediatr Dent"},{"issue":"2","key":"2097_CR24","first-page":"105","volume":"71","author":"M Emirzeoglu","year":"2012","unstructured":"Emirzeoglu M, et al. Estimation of nasal cavity and conchae volumes by stereological method. Folia Morphol (Warsz). 2012;71(2):105\u20138.","journal-title":"Folia Morphol (Warsz)"},{"issue":"1","key":"2097_CR25","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.anl.2005.05.004","volume":"33","author":"A Uzun","year":"2006","unstructured":"Uzun A, et al. The average values of the nasal anthropometric measurements in 108 young Turkish males. Auris Nasus Larynx. 2006;33(1):31\u20135.","journal-title":"Auris Nasus Larynx"},{"issue":"1","key":"2097_CR26","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/S1808-8694(15)31119-8","volume":"73","author":"IE Trindade","year":"2007","unstructured":"Trindade IE, et al. Adult nasal volumes assessed by acoustic rhinometry. Braz J Otorhinolaryngol. 2007;73(1):32\u20139.","journal-title":"Braz J Otorhinolaryngol"},{"issue":"1","key":"2097_CR27","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-017-0157-6","volume":"20","author":"LLB Ponto","year":"2017","unstructured":"Ponto LLB, et al. Pharmacoimaging of blood-brain barrier permeable (FDG) and impermeable (FLT) substrates after intranasal (IN) administration. AAPS J. 2017;20(1):15.","journal-title":"AAPS J"},{"issue":"3","key":"2097_CR28","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics10030116","volume":"10","author":"S G\u00e4nger","year":"2018","unstructured":"G\u00e4nger S, Schindowski K. Tailoring formulations for intranasal nose-to-brain delivery: a review on architecture, physico-chemical characteristics and mucociliary clearance of the nasal olfactory mucosa. Pharmaceutics. 2018;10(3):116.","journal-title":"Pharmaceutics"},{"key":"2097_CR29","doi-asserted-by":"publisher","unstructured":"D\u2019Souza AA, et al. Differential targeting of olfactory epithelium and respiratory epithelium in nose-to-brain drug delivery. Expert Opin Drug Deliv. 2025;(1):20. https:\/\/doi.org\/10.1080\/17425247.2025.2568093.","DOI":"10.1080\/17425247.2025.2568093"},{"key":"2097_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/ftox.2021.750254","volume":"3","author":"K Luettich","year":"2021","unstructured":"Luettich K, et al. An adverse outcome pathway for decreased lung function focusing on mechanisms of impaired mucociliary clearance following inhalation exposure. Front Toxicol. 2021;3:750254.","journal-title":"Front Toxicol"},{"issue":"1","key":"2097_CR31","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.ijpharm.2017.09.018","volume":"532","author":"J Leal","year":"2017","unstructured":"Leal J, Smyth HDC, Ghosh D. Physicochemical properties of mucus and their impact on transmucosal drug delivery. Int J Pharm. 2017;532(1):555\u201372.","journal-title":"Int J Pharm"},{"issue":"10","key":"2097_CR32","first-page":"1315","volume":"29","author":"M Stoeckelhuber","year":"2014","unstructured":"Stoeckelhuber M, et al. Immunolocalization of antimicrobial and cytoskeletal components in the serous glands of human sinonasal mucosa. Histol Histopathol. 2014;29(10):1315\u201324.","journal-title":"Histol Histopathol"},{"issue":"1-2","key":"2097_CR33","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/S0169-409X(97)00059-8","volume":"29","author":"FW Merkus","year":"1998","unstructured":"Merkus FW, et al. Nasal mucociliary clearance as a factor in nasal drug delivery. Adv Drug Deliv Rev. 1998;29(1\u20132):13\u201338.","journal-title":"Adv Drug Deliv Rev"},{"issue":"2","key":"2097_CR34","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.addr.2008.09.008","volume":"61","author":"RA Cone","year":"2009","unstructured":"Cone RA. Barrier properties of mucus. Adv Drug Deliv Rev. 2009;61(2):75\u201385.","journal-title":"Adv Drug Deliv Rev"},{"issue":"7","key":"2097_CR35","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/j.addr.2011.11.002","volume":"64","author":"JJ Lochhead","year":"2012","unstructured":"Lochhead JJ, Thorne RG. Intranasal delivery of biologics to the central nervous system. Adv Drug Deliv Rev. 2012;64(7):614\u201328.","journal-title":"Adv Drug Deliv Rev"},{"issue":"9","key":"2097_CR36","doi-asserted-by":"publisher","first-page":"571","DOI":"10.4155\/tde-2023-0019","volume":"14","author":"SR Babu","year":"2023","unstructured":"Babu SR, et al. Intranasal nanoparticulate delivery systems for neurodegenerative disorders: a review. Ther Deliv. 2023;14(9):571\u201394.","journal-title":"Ther Deliv"},{"key":"2097_CR37","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1111\/j.1749-6632.2009.03894.x","volume":"1170","author":"WL Silver","year":"2009","unstructured":"Silver WL, Finger TE. The anatomical and electrophysiological basis of peripheral nasal trigeminal chemoreception. Ann N Y Acad Sci. 2009;1170:202\u20135.","journal-title":"Ann N Y Acad Sci"},{"issue":"1","key":"2097_CR38","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1093\/chemse\/bjr063","volume":"37","author":"TT Solbu","year":"2012","unstructured":"Solbu TT, Holen T. Aquaporin pathways and mucin secretion of Bowman\u2019s glands might protect the olfactory mucosa. Chem Senses. 2012;37(1):35\u201346.","journal-title":"Chem Senses"},{"key":"2097_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fnana.2015.00031","volume":"9","author":"I Salazar","year":"2015","unstructured":"Salazar I. The nasal cavity and its olfactory sensory territories. Front Neuroanat. 2015;9:31.","journal-title":"Front Neuroanat"},{"key":"2097_CR40","doi-asserted-by":"crossref","unstructured":"D'Souza AA, et al. Differential targeting of olfactory epithelium and respiratory epithelium in nose-to-brain drug delivery. Expert Opin Drug Deliv. 2025:1\u201320.","DOI":"10.1080\/17425247.2025.2568093"},{"key":"2097_CR41","first-page":"xxi","volume-title":"Direct nose-to-brain drug delivery : mechanism, technological advances, applications and regulatory updates,","author":"N Dhas","year":"2021","unstructured":"Dhas N. Chapter 2: Direct transport theory: From the Nose to the Brain. In: Direct nose-to-brain drug delivery\u202f: mechanism, technological advances, applications and regulatory updates,. Amsterdam: Academic Press; 2021. p. xxi\u2013532."},{"issue":"4","key":"2097_CR42","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1007\/s13346-020-00891-5","volume":"12","author":"LA Keller","year":"2022","unstructured":"Keller LA, Merkel O, Popp A. Intranasal drug delivery: opportunities and toxicologic challenges during drug development. Drug Deliv Transl Res. 2022;12(4):735\u201357.","journal-title":"Drug Deliv Transl Res"},{"issue":"1","key":"2097_CR43","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12995-018-0209-6","volume":"13","author":"S Werner","year":"2018","unstructured":"Werner S, Nies E. Olfactory dysfunction revisited: a reappraisal of work-related olfactory dysfunction caused by chemicals. J Occup Med Toxicol. 2018;13:28.","journal-title":"J Occup Med Toxicol"},{"key":"2097_CR44","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.lfs.2017.12.025","volume":"195","author":"TP Crowe","year":"2018","unstructured":"Crowe TP, et al. Mechanism of intranasal drug delivery directly to the brain. Life Sci. 2018;195:44\u201352.","journal-title":"Life Sci"},{"key":"2097_CR45","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.jconrel.2018.08.006","volume":"286","author":"NN Kumar","year":"2018","unstructured":"Kumar NN, et al. Delivery of immunoglobulin G antibodies to the rat nervous system following intranasal administration: distribution, dose-response, and mechanisms of delivery. J Control Release. 2018;286:467\u201384.","journal-title":"J Control Release"},{"key":"2097_CR46","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13122049","author":"D Lee","year":"2021","unstructured":"Lee D, Minko T. Nanotherapeutics for nose-to-brain drug delivery: an approach to bypass the blood brain barrier. Pharmaceutics. 2021. https:\/\/doi.org\/10.3390\/pharmaceutics13122049.","journal-title":"Pharmaceutics"},{"issue":"9","key":"2097_CR47","doi-asserted-by":"publisher","first-page":"2681","DOI":"10.1128\/IAI.00361-16","volume":"84","author":"JA St John","year":"2016","unstructured":"St John JA, et al. Burkholderia pseudomallei rapidly infects the brain stem and spinal cord via the trigeminal nerve after intranasal inoculation. Infect Immun. 2016;84(9):2681\u20138.","journal-title":"Infect Immun"},{"issue":"7","key":"2097_CR48","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1517\/17425247.2013.790887","volume":"10","author":"CV Pardeshi","year":"2013","unstructured":"Pardeshi CV, Belgamwar VS. Direct nose to brain drug delivery via integrated nerve pathways bypassing the blood-brain barrier: an excellent platform for brain targeting. Expert Opin Drug Deliv. 2013;10(7):957\u201372.","journal-title":"Expert Opin Drug Deliv"},{"key":"2097_CR49","doi-asserted-by":"crossref","unstructured":"Qamar Z, et al. Receptor-mediated nose-to-brain delivery of drug combination-loaded polymeric nanocarriers for the treatment of glioblastoma- current progress and future perspectives part I: receptor-mediated nose-to-brain delivery approaches for glioblastoma. Expert Opin Drug Deliv. 2025;1\u201323.","DOI":"10.1080\/17425247.2025.2578384"},{"issue":"1-2","key":"2097_CR50","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.ijpharm.2016.09.042","volume":"513","author":"S Lungare","year":"2016","unstructured":"Lungare S, Hallam K, Badhan RK. Phytochemical-loaded mesoporous silica nanoparticles for nose-to-brain olfactory drug delivery. Int J Pharm. 2016;513(1\u20132):280\u201393.","journal-title":"Int J Pharm"},{"key":"2097_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2020.119957","volume":"590","author":"E Gallardo-Toledo","year":"2020","unstructured":"Gallardo-Toledo E, et al. Intranasal administration of gold nanoparticles designed to target the central nervous system: Fabrication and comparison between nanospheres and nanoprisms. Int J Pharm. 2020;590:119957.","journal-title":"Int J Pharm"},{"issue":"8","key":"2097_CR52","doi-asserted-by":"publisher","first-page":"885","DOI":"10.3109\/17435390.2013.842267","volume":"8","author":"LE Hopkins","year":"2014","unstructured":"Hopkins LE, et al. Nose-to-brain transport of aerosolised quantum dots following acute exposure. Nanotoxicology. 2014;8(8):885\u201393.","journal-title":"Nanotoxicology"},{"key":"2097_CR53","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.jconrel.2024.01.027","volume":"367","author":"S Seino","year":"2024","unstructured":"Seino S, et al. Investigating the efficacy of nasal administration for delivering magnetic nanoparticles into the brain for magnetic particle imaging. J Control Release. 2024;367:515\u201321.","journal-title":"J Control Release"},{"key":"2097_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.apmt.2022.101631","volume":"29","author":"ML Formica","year":"2022","unstructured":"Formica ML, et al. On a highway to the brain: A review on nose-to-brain drug delivery using nanoparticles. Appl Mater Today. 2022;29:101631.","journal-title":"Appl Mater Today"},{"key":"2097_CR55","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.lfs.2019.02.058","volume":"222","author":"HM Fahmy","year":"2019","unstructured":"Fahmy HM, et al. Targeting of Thymoquinone-loaded mesoporous silica nanoparticles to different brain areas: In vivo study. Life Sci. 2019;222:94\u2013102.","journal-title":"Life Sci"},{"key":"2097_CR56","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.jconrel.2018.07.020","volume":"286","author":"D Ye","year":"2018","unstructured":"Ye D, et al. Focused ultrasound combined with microbubble-mediated intranasal delivery of gold nanoclusters to the brain. J Control Release. 2018;286:145\u201353.","journal-title":"J Control Release"},{"key":"2097_CR57","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/978-1-0716-1811-0_26","volume-title":"Biomedical engineering technologies","author":"D Ye","year":"2022","unstructured":"Ye D, Chen H. Focused ultrasound-mediated intranasal brain drug delivery technique (FUSIN). In: Rasooly A, Baker H, Ossandon MR, editors. Biomedical engineering technologies, vol. 2. New York, NY: Springer US; 2022. pp. 501\u201313."},{"key":"2097_CR58","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.jmmm.2018.08.048","volume":"469","author":"S Jafari","year":"2019","unstructured":"Jafari S, et al. Magnetic drilling enhances intra-nasal transport of particles into rodent brain. J Magn Magn Mater. 2019;469:302\u20135.","journal-title":"J Magn Magn Mater"},{"key":"2097_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2019.119342","volume":"218","author":"UK Sukumar","year":"2019","unstructured":"Sukumar UK, et al. Intranasal delivery of targeted polyfunctional gold-iron oxide nanoparticles loaded with therapeutic microRNAs for combined theranostic multimodality imaging and presensitization of glioblastoma to temozolomide. Biomaterials. 2019;218:119342.","journal-title":"Biomaterials"},{"key":"2097_CR60","doi-asserted-by":"publisher","first-page":"9469","DOI":"10.2147\/IJN.S265876","volume":"15","author":"M Hoseini-Ghahfarokhi","year":"2020","unstructured":"Hoseini-Ghahfarokhi M, et al. Applications of graphene and graphene oxide in smart drug\/gene delivery: is the world still flat? Int J Nanomedicine. 2020;15:9469\u201396.","journal-title":"Int J Nanomedicine"},{"issue":"3","key":"2097_CR61","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.nano.2009.11.007","volume":"6","author":"Z Yang","year":"2010","unstructured":"Yang Z, et al. Pharmacological and toxicological target organelles and safe use of single-walled carbon nanotubes as drug carriers in treating Alzheimer disease. Nanomedicine. 2010;6(3):427\u201341.","journal-title":"Nanomedicine"},{"key":"2097_CR62","first-page":"4321","volume":"10","author":"X Feng","year":"2015","unstructured":"Feng X, et al. Central nervous system toxicity of metallic nanoparticles. Int J Nanomedicine. 2015;10:4321\u201340.","journal-title":"Int J Nanomedicine"},{"issue":"6","key":"2097_CR63","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1007\/s12274-014-0697-3","volume":"8","author":"I Fratoddi","year":"2015","unstructured":"Fratoddi I, et al. How toxic are gold nanoparticles? The state-of-the-art Nano Research. 2015;8(6):1771\u201399.","journal-title":"The state-of-the-art Nano Research"},{"issue":"1","key":"2097_CR64","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s11095-022-03433-5","volume":"40","author":"A D'Souza","year":"2023","unstructured":"D\u2019Souza A, et al. CNS delivery of nucleic acid therapeutics: beyond the blood-brain barrier and towards specific cellular targeting. Pharm Res. 2023;40(1):77\u2013105.","journal-title":"Pharm Res"},{"issue":"2","key":"2097_CR65","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/0306-4522(87)90366-6","volume":"22","author":"K Buchner","year":"1987","unstructured":"Buchner K, et al. A quantitative study of anterograde and retrograde axonal transport of exogenous proteins in olfactory nerve C-fibers. Neuroscience. 1987;22(2):697\u2013707.","journal-title":"Neuroscience"},{"issue":"2","key":"2097_CR66","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/0361-9230(85)90129-7","volume":"15","author":"MT Shipley","year":"1985","unstructured":"Shipley MT. Transport of molecules from nose to brain: transneuronal anterograde and retrograde labeling in the rat olfactory system by wheat germ agglutinin-horseradish peroxidase applied to the nasal epithelium. Brain Res Bull. 1985;15(2):129\u201342.","journal-title":"Brain Res Bull"},{"issue":"10","key":"2097_CR67","first-page":"766","volume":"7","author":"H Liu","year":"2012","unstructured":"Liu H, et al. Olfactory route for cerebrospinal fluid drainage into the cervical lymphatic system in a rabbit experimental model. Neural Regen Res. 2012;7(10):766\u201371.","journal-title":"Neural Regen Res"},{"issue":"1","key":"2097_CR68","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1080\/19768354.2024.2307559","volume":"28","author":"J Chae","year":"2024","unstructured":"Chae J, et al. The nasal lymphatic route of CSF outflow: implications for neurodegenerative disease diagnosis and monitoring. Anim Cells Syst. 2024;28(1):45\u201354.","journal-title":"Anim Cells Syst"},{"issue":"1","key":"2097_CR69","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s40005-022-00589-5","volume":"53","author":"S-H Jeong","year":"2023","unstructured":"Jeong S-H, Jang J-H, Lee Y-B. Drug delivery to the brain via the nasal route of administration: exploration of key targets and major consideration factors. J Pharm Investig. 2023;53(1):119\u201352.","journal-title":"J Pharm Investig"},{"issue":"1","key":"2097_CR70","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1211\/0022357022539","volume":"56","author":"L Illum","year":"2004","unstructured":"Illum L. Is nose-to-brain transport of drugs in man a reality? J Pharm Pharmacol. 2004;56(1):3\u201317.","journal-title":"J Pharm Pharmacol"},{"issue":"2","key":"2097_CR71","doi-asserted-by":"publisher","first-page":"195","DOI":"10.4155\/tde.11.149","volume":"3","author":"MS Landis","year":"2012","unstructured":"Landis MS, Boyden T, Pegg S. Nasal-to-CNS drug delivery: where are we now and where are we heading? An industrial perspective. Ther Deliv. 2012;3(2):195\u2013208.","journal-title":"Ther Deliv"},{"issue":"1","key":"2097_CR72","doi-asserted-by":"publisher","DOI":"10.1186\/2045-8118-11-4","volume":"11","author":"H Kim","year":"2014","unstructured":"Kim H, Moore SA, Johnston MG. Potential for intranasal drug delivery to alter cerebrospinal fluid outflow via the nasal turbinate lymphatics. Fluids Barriers CNS. 2014;11(1):4.","journal-title":"Fluids Barriers CNS"},{"issue":"13","key":"2097_CR73","doi-asserted-by":"publisher","first-page":"5022","DOI":"10.7150\/thno.98473","volume":"14","author":"A Almahmoud","year":"2024","unstructured":"Almahmoud A, et al. Intranasal delivery of imaging agents to the brain. Theranostics. 2024;14(13):5022\u2013101.","journal-title":"Theranostics"},{"key":"2097_CR74","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2021.769948","volume":"12","author":"NH Mehta","year":"2021","unstructured":"Mehta NH, et al. The Brain-Nose Interface: A Potential Cerebrospinal Fluid Clearance Site in Humans. Front Physiol. 2021;12:769948.","journal-title":"Front Physiol"},{"issue":"1","key":"2097_CR75","doi-asserted-by":"publisher","first-page":"14974","DOI":"10.1038\/s41598-020-72031-5","volume":"10","author":"E Melin","year":"2020","unstructured":"Melin E, Eide PK, Ringstad G. In vivo assessment of cerebrospinal fluid efflux to nasal mucosa in humans. Sci Rep. 2020;10(1):14974.","journal-title":"Sci Rep"},{"issue":"5","key":"2097_CR76","doi-asserted-by":"publisher","first-page":"4027","DOI":"10.1021\/acsnano.5c12628","volume":"20","author":"G Wang","year":"2026","unstructured":"Wang G, et al. Rabies virus glycoprotein-decorated liposomes in thermosensitive nasal spray gels: facilitating retrograde neural transport for targeted trigeminal neuralgia therapy. ACS Nano. 2026;20(5):4027\u201345.","journal-title":"ACS Nano"},{"key":"2097_CR77","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2016.00108","volume":"9","author":"JY Tan","year":"2016","unstructured":"Tan JY, et al. Non-viral nucleic acid delivery strategies to the central nervous system. Front Mol Neurosci. 2016;9:108.","journal-title":"Front Mol Neurosci"},{"issue":"5","key":"2097_CR78","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1021\/acsnanoscienceau.5c00042","volume":"5","author":"S Mamberti","year":"2025","unstructured":"Mamberti S, et al. On the retrograde transport of RNA-loaded lipid nanoparticles designed for brain delivery. ACS Nanoscience Au. 2025;5(5):375\u201387.","journal-title":"ACS Nanoscience Au"},{"issue":"1","key":"2097_CR79","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.ijpharm.2009.05.009","volume":"377","author":"T Shingaki","year":"2009","unstructured":"Shingaki T, et al. The transnasal delivery of 5-fluorouracil to the rat brain is enhanced by acetazolamide (the inhibitor of the secretion of cerebrospinal fluid). Int J Pharm. 2009;377(1):85\u201391.","journal-title":"Int J Pharm"},{"issue":"5","key":"2097_CR80","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1021\/mp900275s","volume":"7","author":"T Shingaki","year":"2010","unstructured":"Shingaki T, et al. Transnasal delivery of methotrexate to brain tumors in rats: a new strategy for brain tumor chemotherapy. Mol Pharm. 2010;7(5):1561\u20138.","journal-title":"Mol Pharm"},{"issue":"12","key":"2097_CR81","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0248545","volume":"16","author":"MG Pedler","year":"2021","unstructured":"Pedler MG, Petrash JM, Subramanian PS. Prostaglandin analog effects on cerebrospinal fluid reabsorption via nasal mucosa. PLoS One. 2021;16(12):e0248545.","journal-title":"PLoS One"},{"key":"2097_CR82","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.ejpb.2018.05.009","volume":"128","author":"V Bourganis","year":"2018","unstructured":"Bourganis V, et al. Recent advances in carrier mediated nose-to-brain delivery of pharmaceutics. Eur J Pharm Biopharm. 2018;128:337\u201362.","journal-title":"Eur J Pharm Biopharm"},{"issue":"5","key":"2097_CR83","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1089\/jamp.2019.1549","volume":"33","author":"SB Yarragudi","year":"2020","unstructured":"Yarragudi SB, et al. Olfactory targeting of microparticles through inhalation and bi-directional airflow: effect of particle size and nasal anatomy. J Aerosol Med Pulm Drug Deliv. 2020;33(5):258\u201370.","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"issue":"1\u20132","key":"2097_CR84","first-page":"3","volume":"29","author":"R Dahl","year":"1998","unstructured":"Dahl R, Mygind N. Anatomy, physiology and function of the nasal cavities in health and disease. Adv Drug Deliv Rev. 1998;29(1\u20132):3\u201312.","journal-title":"Adv Drug Deliv Rev"},{"key":"2097_CR85","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15051557","author":"M Usman Khan","year":"2023","unstructured":"Usman Khan M, et al. Challenges in the development and application of organ-on-chips for intranasal drug delivery studies. Pharmaceutics. 2023. https:\/\/doi.org\/10.3390\/pharmaceutics15051557.","journal-title":"Pharmaceutics"},{"key":"2097_CR86","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebr.2022.100581","volume":"21","author":"S Chung","year":"2023","unstructured":"Chung S, et al. The nose has it: Opportunities and challenges for intranasal drug administration for neurologic conditions including seizure clusters. Epilepsy Behav Rep. 2023;21:100581.","journal-title":"Epilepsy Behav Rep"},{"key":"2097_CR87","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15082119","author":"S Madden","year":"2023","unstructured":"Madden S, Carrazana E, Rabinowicz AL. Optimizing absorption for intranasal delivery of drugs targeting the central nervous system using alkylsaccharide permeation enhancers. Pharmaceutics. 2023. https:\/\/doi.org\/10.3390\/pharmaceutics15082119.","journal-title":"Pharmaceutics"},{"key":"2097_CR88","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2019.118635","volume":"570","author":"PP Martins","year":"2019","unstructured":"Martins PP, Smyth HDC, Cui Z. Strategies to facilitate or block nose-to-brain drug delivery. Int J Pharm. 2019;570:118635.","journal-title":"Int J Pharm"},{"issue":"7","key":"2097_CR89","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1007\/s40263-022-00930-4","volume":"36","author":"A Lofts","year":"2022","unstructured":"Lofts A, et al. Using the intranasal route to administer drugs to treat neurological and psychiatric illnesses: rationale, successes, and future needs. CNS Drugs. 2022;36(7):739\u201370.","journal-title":"CNS Drugs"},{"issue":"4","key":"2097_CR90","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/j.apsb.2021.02.012","volume":"11","author":"CP Costa","year":"2021","unstructured":"Costa CP, et al. Intranasal delivery of nanostructured lipid carriers, solid lipid nanoparticles and nanoemulsions: a current overview of in\u00a0vivo studies. Acta Pharm Sin B. 2021;11(4):925\u201340.","journal-title":"Acta Pharm Sin B"},{"key":"2097_CR91","doi-asserted-by":"publisher","DOI":"10.3390\/encyclopedia5030091","author":"LT Nguyen","year":"2025","unstructured":"Nguyen LT, Duong V-A. Nose-to-brain drug delivery. Encyclopedia. 2025. https:\/\/doi.org\/10.3390\/encyclopedia5030091.","journal-title":"Encyclopedia"},{"key":"2097_CR92","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.jconrel.2018.12.049","volume":"295","author":"C Costa","year":"2019","unstructured":"Costa C, et al. Nose-to-brain delivery of lipid-based nanosystems for epileptic seizures and anxiety crisis. J Control Release. 2019;295:187\u2013200.","journal-title":"J Control Release"},{"key":"2097_CR93","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jconrel.2017.11.047","volume":"270","author":"PC Pires","year":"2018","unstructured":"Pires PC, Santos AO. Nanosystems in nose-to-brain drug delivery: a review of non-clinical brain targeting studies. J Control Release. 2018;270:89\u2013100.","journal-title":"J Control Release"},{"key":"2097_CR94","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics16060746","author":"H Omidian","year":"2024","unstructured":"Omidian H, et al. Chitosan nanoparticles for intranasal drug delivery. Pharmaceutics. 2024. https:\/\/doi.org\/10.3390\/pharmaceutics16060746.","journal-title":"Pharmaceutics"},{"key":"2097_CR95","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2021.113826","volume":"175","author":"L Deruyver","year":"2021","unstructured":"Deruyver L, et al. The importance of pre-formulation studies and of 3D-printed nasal casts in the success of a pharmaceutical product intended for nose-to-brain delivery. Adv Drug Deliv Rev. 2021;175:113826.","journal-title":"Adv Drug Deliv Rev"},{"issue":"12","key":"2097_CR96","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1080\/17425247.2025.2568086","volume":"22","author":"A Seifelnasr","year":"2025","unstructured":"Seifelnasr A, et al. Improving nasal spray deposition: advances and strategies to overcome anatomical and physiological barriers. Expert Opin Drug Deliv. 2025;22(12):1895\u2013914.","journal-title":"Expert Opin Drug Deliv"},{"issue":"1","key":"2097_CR97","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1007\/s13346-012-0108-9","volume":"3","author":"PG Djupesland","year":"2013","unstructured":"Djupesland PG. Nasal drug delivery devices: characteristics and performance in a clinical perspective-a review. Drug Deliv Transl Res. 2013;3(1):42\u201362.","journal-title":"Drug Deliv Transl Res"},{"issue":"2","key":"2097_CR98","first-page":"137","volume":"46","author":"S Yu","year":"2008","unstructured":"Yu S, et al. Influence of nasal structure on the distribution of airflow in nasal cavity. Rhinology. 2008;46(2):137\u201343.","journal-title":"Rhinology"},{"issue":"2","key":"2097_CR99","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/S1808-8694(15)30795-3","volume":"75","author":"CE Nigro","year":"2009","unstructured":"Nigro CE, et al. Nasal valve: anatomy and physiology. Braz J Otorhinolaryngol. 2009;75(2):305\u201310.","journal-title":"Braz J Otorhinolaryngol"},{"issue":"3","key":"2097_CR100","doi-asserted-by":"publisher","first-page":"288","DOI":"10.18433\/J3NC79","volume":"12","author":"A Pires","year":"2009","unstructured":"Pires A, et al. Intranasal drug delivery: how, why and what for? J Pharm Pharm Sci. 2009;12(3):288\u2013311.","journal-title":"J Pharm Pharm Sci"},{"key":"2097_CR101","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.jconrel.2016.07.001","volume":"237","author":"M Kapoor","year":"2016","unstructured":"Kapoor M, Cloyd JC, Siegel RA. A review of intranasal formulations for the treatment of seizure emergencies. J Control Release. 2016;237:147\u201359.","journal-title":"J Control Release"},{"issue":"5","key":"2097_CR102","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0036167","volume":"7","author":"A Molinas","year":"2012","unstructured":"Molinas A, Sicard G, Jakob I. Functional evidence of multidrug resistance transporters (MDR) in rodent olfactory epithelium. PLoS One. 2012;7(5):e36167.","journal-title":"PLoS One"},{"issue":"7","key":"2097_CR103","doi-asserted-by":"publisher","first-page":"628","DOI":"10.2174\/1389200217666160406120509","volume":"17","author":"P Oliveira","year":"2016","unstructured":"Oliveira P, et al. Drug-metabolizing enzymes and efflux transporters in nasal epithelium: influence on the bioavailability of intranasally administered drugs. Curr Drug Metab. 2016;17(7):628\u201347.","journal-title":"Curr Drug Metab"},{"issue":"2","key":"2097_CR104","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1183\/20734735.000318","volume":"14","author":"A LoMauro","year":"2018","unstructured":"LoMauro A, Aliverti A. Sex differences in respiratory function. Breathe Sheff. 2018;14(2):131\u201340.","journal-title":"Breathe Sheff"},{"key":"2097_CR105","doi-asserted-by":"publisher","first-page":"242","DOI":"10.3389\/fpsyg.2019.00242","volume":"10","author":"P Sorokowski","year":"2019","unstructured":"Sorokowski P, et al. Sex Differences in Human Olfaction: A Meta-Analysis. Front Psychol. 2019;10:242.","journal-title":"Front Psychol"},{"issue":"3","key":"2097_CR106","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1093\/gerona\/glt063","volume":"69","author":"JM Pinto","year":"2014","unstructured":"Pinto JM, et al. Racial disparities in olfactory loss among older adults in the United States. J Gerontol A Biol Sci Med Sci. 2014;69(3):323\u20139.","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"2097_CR107","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/1471-2202-13-122","volume":"13","author":"A Keller","year":"2012","unstructured":"Keller A, et al. An olfactory demography of a diverse metropolitan population. BMC Neurosci. 2012;13:122.","journal-title":"BMC Neurosci"},{"key":"2097_CR108","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics11030113","author":"M Ghadiri","year":"2019","unstructured":"Ghadiri M, Young PM, Traini D. Strategies to enhance drug absorption via nasal and pulmonary routes. Pharmaceutics. 2019. https:\/\/doi.org\/10.3390\/pharmaceutics11030113.","journal-title":"Pharmaceutics"},{"key":"2097_CR109","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2024.124851","volume":"667","author":"M Pasteur","year":"2024","unstructured":"Pasteur M, et al. Characterization of anatomical variations of the nasal cavity in a subset of European patients and their impact on intranasal drug delivery. Int J Pharm. 2024;667:124851.","journal-title":"Int J Pharm"},{"key":"2097_CR110","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics16070929","author":"Y Ge","year":"2024","unstructured":"Ge Y, et al. Nasal drug delivery and nose-to-brain delivery technology development status and trend analysis: based on questionnaire survey and patent analysis. Pharmaceutics. 2024. https:\/\/doi.org\/10.3390\/pharmaceutics16070929.","journal-title":"Pharmaceutics"},{"key":"2097_CR111","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.jconrel.2018.05.011","volume":"281","author":"M Agrawal","year":"2018","unstructured":"Agrawal M, et al. Nose-to-brain drug delivery: an update on clinical challenges and progress towards approval of anti-Alzheimer drugs. J Control Release. 2018;281:139\u201377.","journal-title":"J Control Release"},{"issue":"1","key":"2097_CR112","doi-asserted-by":"publisher","first-page":"115","DOI":"10.2174\/1567201820666221214105836","volume":"21","author":"A Haasbroek-Pheiffer","year":"2024","unstructured":"Haasbroek-Pheiffer A, et al. An Ex vivo Investigation on Drug Permeability of Sheep Nasal Epithelial Tissue Membranes from the Respiratory and Olfactory Regions. Curr Drug Deliv. 2024;21(1):115\u201325.","journal-title":"Curr Drug Deliv"},{"key":"2097_CR113","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15051423","volume":"15","author":"A Haasbroek-Pheiffer","year":"2023","unstructured":"Haasbroek-Pheiffer A, et al. Permeation of phytochemicals of selected psychoactive medicinal plants across excised sheep respiratory and olfactory epithelial tissues. Pharmaceutics. 2023;15:10.3390\/pharmaceutics15051423.","journal-title":"Pharmaceutics"},{"issue":"5","key":"2097_CR114","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1177\/0145561320961004","volume":"100","author":"EL Cummings","year":"2021","unstructured":"Cummings EL, et al. Positional Installation of Intranasal Corticosteroids in the Treatment of Chronic Rhinosinusitis: A Systematic Review of the Literature. Ear Nose Throat J. 2021;100(5):302\u20138.","journal-title":"Ear Nose Throat J"},{"issue":"5","key":"2097_CR115","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1177\/0145561320961004","volume":"100","author":"EL Cummings","year":"2020","unstructured":"Cummings EL, et al. Positional installation of intranasal corticosteroids in the treatment of chronic rhinosinusitis: a systematic review of the literature. Ear Nose Throat J. 2020;100(5):302\u20138.","journal-title":"Ear Nose Throat J"},{"key":"2097_CR116","doi-asserted-by":"publisher","DOI":"10.1016\/j.mtbio.2025.101652","volume":"32","author":"G Wan","year":"2025","unstructured":"Wan G, et al. Endoscopic nasal delivery of engineered endothelial progenitor cell-derived exosomes improves angiogenesis and neurological deficits in rats with intracerebral hemorrhage. Materials Today Bio. 2025;32:101652.","journal-title":"Materials Today Bio"},{"key":"2097_CR117","doi-asserted-by":"publisher","DOI":"10.1038\/s41684-024-01460-w","author":"AJ Chua","year":"2024","unstructured":"Chua AJ, et al. Murine model of minimally invasive nasal depot (MIND) technique for central nervous system delivery of blood\u2013brain barrier-impermeant therapeutics. Lab Anim. 2024. https:\/\/doi.org\/10.1038\/s41684-024-01460-w.","journal-title":"Lab Anim"},{"issue":"2","key":"2097_CR118","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/S0169-409X(98)00073-8","volume":"35","author":"M Hinchcliffe","year":"1999","unstructured":"Hinchcliffe M, Illum L. Intranasal insulin delivery and therapy. Adv Drug Deliv Rev. 1999;35(2):199\u2013234.","journal-title":"Adv Drug Deliv Rev"},{"key":"2097_CR119","doi-asserted-by":"publisher","DOI":"10.1016\/j.nantod.2020.100898","author":"A Vedadghavami","year":"2020","unstructured":"Vedadghavami A, Zhang C, Bajpayee AG. Overcoming negatively charged tissue barriers: drug delivery using cationic peptides and proteins. Nano Today. 2020. https:\/\/doi.org\/10.1016\/j.nantod.2020.100898.","journal-title":"Nano Today"},{"key":"2097_CR120","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.ejpb.2015.11.003","volume":"98","author":"K Netsomboon","year":"2016","unstructured":"Netsomboon K, Bernkop-Schn\u00fcrch A. Mucoadhesive vs. mucopenetrating particulate drug delivery. Eur J Pharm Biopharm. 2016;98:76\u201389.","journal-title":"Eur J Pharm Biopharm"},{"issue":"5","key":"2097_CR121","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1073\/pnas.0608611104","volume":"104","author":"SK Lai","year":"2007","unstructured":"Lai SK, et al. Rapid transport of large polymeric nanoparticles in fresh undiluted human mucus. Proc Natl Acad Sci U S A. 2007;104(5):1482\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2097_CR122","doi-asserted-by":"publisher","DOI":"10.3390\/gels8120796","author":"N Menshutina","year":"2022","unstructured":"Menshutina N, et al. Chitosan aerogel particles as nasal drug delivery systems. Gels. 2022. https:\/\/doi.org\/10.3390\/gels8120796.","journal-title":"Gels"},{"key":"2097_CR123","doi-asserted-by":"publisher","DOI":"10.3390\/polym10030267","author":"MW Tm","year":"2018","unstructured":"Tm MW, Lau WM, Khutoryanskiy VV. Chitosan and its derivatives for application in mucoadhesive drug delivery systems. Polymers (Basel). 2018. https:\/\/doi.org\/10.3390\/polym10030267.","journal-title":"Polymers (Basel)"},{"key":"2097_CR124","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.2147\/IJN.S439181","volume":"19","author":"J Koo","year":"2024","unstructured":"Koo J, Lim C, Oh KT. Recent advances in intranasal administration for brain-targeting delivery: a comprehensive review of lipid-based nanoparticles and stimuli-responsive gel formulations. Int J Nanomedicine. 2024;19:1767\u2013807.","journal-title":"Int J Nanomedicine"},{"key":"2097_CR125","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.jconrel.2014.06.053","volume":"189","author":"L Kozlovskaya","year":"2014","unstructured":"Kozlovskaya L, Abou-Kaoud M, Stepensky D. Quantitative analysis of drug delivery to the brain via nasal route. J Control Release. 2014;189:133\u201340.","journal-title":"J Control Release"},{"issue":"4","key":"2097_CR126","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1080\/17425247.2025.2470224","volume":"22","author":"F Brako","year":"2025","unstructured":"Brako F, Boateng J. Transmucosal drug delivery: prospects, challenges, advances, and future directions. Expert Opin Drug Deliv. 2025;22(4):525\u201353.","journal-title":"Expert Opin Drug Deliv"},{"key":"2097_CR127","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.jconrel.2020.07.044","volume":"327","author":"M Agrawal","year":"2020","unstructured":"Agrawal M, et al. Stimuli-responsive in situ gelling system for nose-to-brain drug delivery. J Control Release. 2020;327:235\u201365.","journal-title":"J Control Release"},{"issue":"6","key":"2097_CR128","doi-asserted-by":"publisher","DOI":"10.1002\/mame.202400356","volume":"310","author":"L Qian","year":"2025","unstructured":"Qian L, Cook MT, Dreiss CA. In situ gels for nasal delivery: formulation, characterization and applications. Macromol Mater Eng. 2025;310(6):2400356.","journal-title":"Macromol Mater Eng"},{"key":"2097_CR129","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.jddst.2016.05.003","volume":"35","author":"ZN Warnken","year":"2016","unstructured":"Warnken ZN, et al. Formulation and device design to increase nose to brain drug delivery. J Drug Deliv Sci Technol. 2016;35:213\u201322.","journal-title":"J Drug Deliv Sci Technol"},{"issue":"3","key":"2097_CR130","doi-asserted-by":"publisher","first-page":"180","DOI":"10.2337\/diaspect.29.3.180","volume":"29","author":"J Oleck","year":"2016","unstructured":"Oleck J, Kassam S, Goldman JD. Commentary: why was inhaled insulin a failure in the market? Diabetes Spectr. 2016;29(3):180\u20134.","journal-title":"Diabetes Spectr"},{"issue":"4","key":"2097_CR131","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1021\/acs.molpharmaceut.7b00702","volume":"15","author":"ZN Warnken","year":"2018","unstructured":"Warnken ZN, et al. Personalized medicine in nasal delivery: the use of patient-specific administration parameters to improve nasal drug targeting using 3D-printed nasal replica casts. Mol Pharm. 2018;15(4):1392\u2013402.","journal-title":"Mol Pharm"},{"issue":"2","key":"2097_CR132","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1177\/0194599811427519","volume":"146","author":"DO Frank","year":"2012","unstructured":"Frank DO, et al. Effects of anatomy and particle size on nasal sprays and nebulizers. Otolaryngol Head Neck Surg. 2012;146(2):313\u20139.","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"6","key":"2097_CR133","doi-asserted-by":"publisher","DOI":"10.1208\/s12249-025-03171-y","volume":"26","author":"S Lobo","year":"2025","unstructured":"Lobo S, et al. Intranasal delivery: formulation factors and insights into user experience. AAPS PharmSciTech. 2025;26(6):179.","journal-title":"AAPS PharmSciTech"},{"issue":"5","key":"2097_CR134","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1089\/jamp.2011.0924","volume":"25","author":"PG Djupesland","year":"2012","unstructured":"Djupesland PG, Skretting A. Nasal deposition and clearance in man: comparison of a bidirectional powder device and a traditional liquid spray pump. J Aerosol Med Pulm Drug Deliv. 2012;25(5):280\u20139.","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"issue":"3\u20134","key":"2097_CR135","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.ejps.2006.11.018","volume":"30","author":"S Charlton","year":"2007","unstructured":"Charlton S, et al. Distribution and clearance of bioadhesive formulations from the olfactory region in man: effect of polymer type and nasal delivery device. Eur J Pharm Sci. 2007;30(3\u20134):295\u2013302.","journal-title":"Eur J Pharm Sci"},{"key":"2097_CR136","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/B978-0-12-822522-6.00020-5","volume-title":"Direct nose-to-brain drug delivery","author":"SR Shahi","year":"2021","unstructured":"Shahi SR, Pardeshi CV. Chapter 21 - A technology overview on advanced drug administration devices for effective nose-to-brain delivery. In: Pardeshi CV, Souto EB, editors. Direct nose-to-brain drug delivery. Academic Press; 2021. pp. 417\u201327."},{"issue":"8","key":"2097_CR137","doi-asserted-by":"publisher","DOI":"10.1208\/s12249-024-02946-z","volume":"25","author":"M Butola","year":"2024","unstructured":"Butola M, Nainwal N. Non-invasive techniques of nose to brain delivery using nanoparticulate carriers: hopes and hurdles. AAPS PharmSciTech. 2024;25(8):256.","journal-title":"AAPS PharmSciTech"},{"key":"2097_CR138","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15061720","author":"SB Shrewsbury","year":"2023","unstructured":"Shrewsbury SB. The upper nasal space: option for systemic drug delivery, mucosal vaccines and \u201cNose-to-Brain.\u201d Pharmaceutics. 2023. https:\/\/doi.org\/10.3390\/pharmaceutics15061720.","journal-title":"Pharmaceutics"},{"key":"2097_CR139","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13071079","author":"A Maaz","year":"2021","unstructured":"Maaz A, Blagbrough IS, De Bank PA. In vitro evaluation of nasal aerosol depositions: an insight for direct nose to brain drug delivery. Pharmaceutics. 2021. https:\/\/doi.org\/10.3390\/pharmaceutics13071079.","journal-title":"Pharmaceutics"},{"key":"2097_CR140","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/j.jconrel.2021.12.009","volume":"341","author":"H Goel","year":"2022","unstructured":"Goel H, et al. Convolutions in the rendition of nose to brain therapeutics from bench to bedside: feats & fallacies. J Control Release. 2022;341:782\u2013811.","journal-title":"J Control Release"},{"key":"2097_CR141","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.jneumeth.2017.05.012","volume":"286","author":"JKS Krishnan","year":"2017","unstructured":"Krishnan JKS, et al. Effect of administration method, animal weight and age on the intranasal delivery of drugs to the brain. J Neurosci Methods. 2017;286:16\u201321.","journal-title":"J Neurosci Methods"},{"issue":"1","key":"2097_CR142","doi-asserted-by":"publisher","DOI":"10.1186\/s40035-025-00481-w","volume":"14","author":"I Drath","year":"2025","unstructured":"Drath I, Richter F, Feja M. Nose-to-brain drug delivery: from bench to bedside. Transl Neurodegener. 2025;14(1):23.","journal-title":"Transl Neurodegener"},{"issue":"7","key":"2097_CR143","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1080\/10611860903055470","volume":"17","author":"A Mistry","year":"2009","unstructured":"Mistry A, et al. Effect of physicochemical properties on intranasal nanoparticle transit into murine olfactory epithelium. J Drug Target. 2009;17(7):543\u201352.","journal-title":"J Drug Target"},{"key":"2097_CR144","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.jconrel.2023.06.005","volume":"359","author":"K Sasaki","year":"2023","unstructured":"Sasaki K, et al. Effective nose-to-brain drug delivery using a combination system targeting the olfactory region in monkeys. J Control Release. 2023;359:384\u201399.","journal-title":"J Control Release"},{"issue":"13","key":"2097_CR145","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.2165\/00003088-200342130-00003","volume":"42","author":"SS Davis","year":"2003","unstructured":"Davis SS, Illum L. Absorption enhancers for nasal drug delivery. Clin Pharmacokinet. 2003;42(13):1107\u201328.","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"2097_CR146","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1124\/jpet.108.145565","volume":"328","author":"SV Dhuria","year":"2009","unstructured":"Dhuria SV, Hanson LR, Frey WH II. Novel vasoconstrictor formulation to enhance intranasal targeting of neuropeptide therapeutics to the central nervous system. J Pharmacol Exp Ther. 2009;328(1):312\u201320.","journal-title":"J Pharmacol Exp Ther"},{"issue":"5","key":"2097_CR147","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1080\/10611860701393370","volume":"15","author":"ST Charlton","year":"2007","unstructured":"Charlton ST, Davis SS, Illum L. Evaluation of effect of ephedrine on the transport of drugs from the nasal cavity to the systemic circulation and the central nervous system. J Drug Target. 2007;15(5):370\u20137.","journal-title":"J Drug Target"},{"issue":"3","key":"2097_CR148","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/0378-5173(86)90153-5","volume":"31","author":"GSMJE Duchateau","year":"1986","unstructured":"Duchateau GSMJE, Zuidema J, Merkus FWHM. Bile salts and intranasal drug absorption. Int J Pharm. 1986;31(3):193\u20139.","journal-title":"Int J Pharm"},{"issue":"2","key":"2097_CR149","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/0378-5173(81)90010-7","volume":"9","author":"H Shinichiro","year":"1981","unstructured":"Shinichiro H, Takatsuka Y, Hiroyuki M. Mechanisms for the enhancement of the nasal absorption of insulin by surfactants. Int J Pharm. 1981;9(2):173\u201384.","journal-title":"Int J Pharm"},{"issue":"5","key":"2097_CR150","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1002\/jps.2600760502","volume":"76","author":"JP Longenecker","year":"1987","unstructured":"Longenecker JP, et al. Effects of sodium taurodihydrofusidate on nasal absorption of insulin in sheep. J Pharm Sci. 1987;76(5):351\u20135.","journal-title":"J Pharm Sci"},{"issue":"2","key":"2097_CR151","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/0378-5173(94)00308-R","volume":"117","author":"SG Chandler","year":"1995","unstructured":"Chandler SG, Thomas NW, Illum l. Nasal absorption in the rat: IV. Membrane activity of absorption enhancers. Int J Pharm. 1995;117(2):139\u201346.","journal-title":"Int J Pharm"},{"issue":"3","key":"2097_CR152","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1111\/j.2042-7158.1991.tb06662.x","volume":"43","author":"AH Batts","year":"1991","unstructured":"Batts AH, et al. The use of a radiolabelled saccharin solution to monitor the effect of the preservatives thiomersal, benzalkonium chloride and EDTA on human nasal clearance. J Pharm Pharmacol. 1991;43(3):180\u20135.","journal-title":"J Pharm Pharmacol"},{"issue":"12","key":"2097_CR153","doi-asserted-by":"publisher","first-page":"6342","DOI":"10.1016\/j.apsb.2025.10.026","volume":"15","author":"M Liu","year":"2025","unstructured":"Liu M, et al. Progress in peptide and protein therapeutics: challenges and strategies. Acta Pharm Sin B. 2025;15(12):6342\u201381.","journal-title":"Acta Pharm Sin B"},{"key":"2097_CR154","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2025.125598","volume":"678","author":"S Hong","year":"2025","unstructured":"Hong S, et al. Advances in cell-penetrating peptide-based nose-to-brain drug delivery systems. Int J Pharm. 2025;678:125598.","journal-title":"Int J Pharm"},{"key":"2097_CR155","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13111745","author":"N Kamei","year":"2021","unstructured":"Kamei N, et al. Investigation of the transport pathways associated with enhanced brain delivery of peptide drugs by intranasal coadministration with Penetratin. Pharmaceutics. 2021. https:\/\/doi.org\/10.3390\/pharmaceutics13111745.","journal-title":"Pharmaceutics"},{"issue":"1","key":"2097_CR156","doi-asserted-by":"publisher","first-page":"3104","DOI":"10.1038\/s41598-019-39495-6","volume":"9","author":"A Robert-Hazotte","year":"2019","unstructured":"Robert-Hazotte A, et al. Nasal mucus glutathione transferase activity and impact on olfactory perception and neonatal behavior. Sci Rep. 2019;9(1):3104.","journal-title":"Sci Rep"},{"issue":"1","key":"2097_CR157","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3109\/10717544.2013.840017","volume":"21","author":"M Krishan","year":"2014","unstructured":"Krishan M, et al. Manipulation of olfactory tight junctions using papaverine to enhance intranasal delivery of gemcitabine to the brain. Drug Deliv. 2014;21(1):8\u201316.","journal-title":"Drug Deliv"},{"key":"2097_CR158","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2025.125584","volume":"676","author":"S Wei","year":"2025","unstructured":"Wei S, et al. The review of nasal drug delivery system: the strategies to enhance the efficiency of intranasal drug delivery by improving drug absorption. Int J Pharm. 2025;676:125584.","journal-title":"Int J Pharm"},{"issue":"3","key":"2097_CR159","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1021\/acs.molpharmaceut.3c00588","volume":"21","author":"E Taha","year":"2024","unstructured":"Taha E, et al. Versatile nanoparticulate systems as a prosperous platform for targeted nose-brain drug delivery. Mol Pharm. 2024;21(3):999\u20131014.","journal-title":"Mol Pharm"},{"issue":"7","key":"2097_CR160","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1208\/s12249-023-02625-5","volume":"24","author":"S Singh","year":"2023","unstructured":"Singh S, Shukla R. Nanovesicular-mediated intranasal drug therapy for neurodegenerative disease. AAPS PharmSciTech. 2023;24(7):179.","journal-title":"AAPS PharmSciTech"},{"key":"2097_CR161","doi-asserted-by":"publisher","DOI":"10.3390\/molecules25081929","author":"SU Islam","year":"2020","unstructured":"Islam SU, et al. Intranasal delivery of nanoformulations: a potential way of treatment for neurological disorders. Molecules. 2020. https:\/\/doi.org\/10.3390\/molecules25081929.","journal-title":"Molecules"},{"issue":"3","key":"2097_CR162","doi-asserted-by":"publisher","first-page":"681","DOI":"10.3109\/10717544.2014.920431","volume":"23","author":"A Kumar","year":"2016","unstructured":"Kumar A, Pandey AN, Jain SK. Nasal-nanotechnology: revolution for efficient therapeutics delivery. Drug Deliv. 2016;23(3):681\u201393.","journal-title":"Drug Deliv"},{"issue":"8","key":"2097_CR163","doi-asserted-by":"publisher","DOI":"10.1208\/s12249-024-02974-9","volume":"25","author":"MVG Botan","year":"2024","unstructured":"Botan MVG, da Silva JB, Bruschi ML. Technological strategies applied to pharmaceutical systems for intranasal administration of drugs intended for neurological treatments: a review. AAPS PharmSciTech. 2024;25(8):258.","journal-title":"AAPS PharmSciTech"},{"issue":"1","key":"2097_CR164","doi-asserted-by":"publisher","first-page":"20230158","DOI":"10.1515\/ntrev-2023-0158","volume":"12","author":"S Guo","year":"2023","unstructured":"Guo S, Yi C-X. Cell type-targeting nanoparticles in treating central nervous system diseases: challenges and hopes. Nanotechnol Rev. 2023;12(1):20230158.","journal-title":"Nanotechnol Rev"},{"key":"2097_CR165","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.jconrel.2017.05.019","volume":"260","author":"M Agrawal","year":"2017","unstructured":"Agrawal M, et al. Recent advancements in liposomes targeting strategies to cross blood-brain barrier (BBB) for the treatment of Alzheimer\u2019s disease. J Control Release. 2017;260:61\u201377.","journal-title":"J Control Release"},{"issue":"1","key":"2097_CR166","doi-asserted-by":"publisher","DOI":"10.1186\/s43556-020-00019-8","volume":"1","author":"A Sarma","year":"2020","unstructured":"Sarma A, Das MK. Nose to brain delivery of antiretroviral drugs in the treatment of neuroAIDS. Mol Biomed. 2020;1(1):15.","journal-title":"Mol Biomed"},{"issue":"4","key":"2097_CR167","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1166\/jbn.2019.2724","volume":"15","author":"Y Li","year":"2019","unstructured":"Li Y, et al. The trigeminal pathway dominates the nose-to-brain transportation of intact polymeric nanoparticles: evidence from aggregation-caused quenching probes. J Biomed Nanotechnol. 2019;15(4):686\u2013702.","journal-title":"J Biomed Nanotechnol"},{"issue":"2","key":"2097_CR168","doi-asserted-by":"publisher","DOI":"10.1208\/s12249-022-02209-9","volume":"23","author":"A Rajput","year":"2022","unstructured":"Rajput A, Butani S. Donepezil HCl liposomes: development, characterization, cytotoxicity, and pharmacokinetic study. AAPS PharmSciTech. 2022;23(2):74.","journal-title":"AAPS PharmSciTech"},{"issue":"12","key":"2097_CR169","doi-asserted-by":"publisher","first-page":"3837","DOI":"10.1007\/s11095-015-1744-9","volume":"32","author":"X Zheng","year":"2015","unstructured":"Zheng X, et al. Intranasal H102 peptide-loaded liposomes for brain delivery to treat Alzheimer\u2019s disease. Pharm Res. 2015;32(12):3837\u201349.","journal-title":"Pharm Res"},{"key":"2097_CR170","doi-asserted-by":"publisher","DOI":"10.1016\/j.mtbio.2023.100789","volume":"22","author":"T Yin","year":"2023","unstructured":"Yin T, et al. Cell primitive-based biomimetic nanomaterials for Alzheimer\u2019s disease targeting and therapy. Mater Today Bio. 2023;22:100789.","journal-title":"Mater Today Bio"},{"issue":"4","key":"2097_CR171","doi-asserted-by":"publisher","DOI":"10.1002\/wnan.70025","volume":"17","author":"V Sundaram","year":"2025","unstructured":"Sundaram V, Aryal S. Emerging biomimetic drug delivery nanoparticles inspired by extracellular vesicles. WIREs Nanomed Nanobiotechnol. 2025;17(4):e70025.","journal-title":"WIREs Nanomed Nanobiotechnol"},{"issue":"1","key":"2097_CR172","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1021\/acsami.4c16837","volume":"17","author":"NN Ferreira","year":"2025","unstructured":"Ferreira NN, et al. Nose-to-Brain Delivery of Biomimetic Nanoparticles for Glioblastoma Targeted Therapy. ACS Appl Mater Interfaces. 2025;17(1):484\u201399.","journal-title":"ACS Appl Mater Interfaces"},{"key":"2097_CR173","doi-asserted-by":"publisher","DOI":"10.1093\/rb\/rbaf063","volume":"12","author":"Y Wu","year":"2025","unstructured":"Wu Y, et al. Functionalized biomimetic nanoparticles are delivered from the nose to the brain for the synergistic targeted treatment of cerebral ischemia\/reperfusion injury. Regen Biomater. 2025;12:rbaf063.","journal-title":"Regen Biomater"},{"key":"2097_CR174","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2025.01.017","author":"H Shen","year":"2025","unstructured":"Shen H, et al. Engineered commensals for targeted nose-to-brain drug delivery. Cell. 2025. https:\/\/doi.org\/10.1016\/j.cell.2025.01.017.","journal-title":"Cell"},{"issue":"1-2","key":"2097_CR175","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.ijpharm.2007.03.039","volume":"340","author":"X Gao","year":"2007","unstructured":"Gao X, et al. UEA I-bearing nanoparticles for brain delivery following intranasal administration. Int J Pharm. 2007;340(1\u20132):207\u201315.","journal-title":"Int J Pharm"},{"issue":"2","key":"2097_CR176","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.jconrel.2011.02.022","volume":"151","author":"Z Wen","year":"2011","unstructured":"Wen Z, et al. Odorranalectin-conjugated nanoparticles: preparation, brain delivery and pharmacodynamic study on Parkinson\u2019s disease following intranasal administration. J Control Release. 2011;151(2):131\u20138.","journal-title":"J Control Release"},{"issue":"1","key":"2097_CR177","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.neuroscience.2008.05.040","volume":"155","author":"Q Zhang","year":"2008","unstructured":"Zhang Q. Nasal administration of cholera toxin B subunit\u2013nerve growth factor improves the space learning and memory abilities in \u03b2-amyloid protein25-35-induced amnesic mice. Neuroscience. 2008;155(1):234\u201340.","journal-title":"Neuroscience"},{"key":"2097_CR178","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.943772","volume":"13","author":"A Dalvi","year":"2022","unstructured":"Dalvi A, Ravi PR, Uppuluri CT. Design and evaluation of rufinamide nanocrystals loaded thermoresponsive nasal in situ gelling system for improved drug distribution to brain. Front Pharmacol. 2022;13:943772.","journal-title":"Front Pharmacol"},{"issue":"1","key":"2097_CR179","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.ijpharm.2009.06.019","volume":"379","author":"A Mistry","year":"2009","unstructured":"Mistry A, Stolnik S, Illum L. Nanoparticles for direct nose-to-brain delivery of drugs. Int J Pharm. 2009;379(1):146\u201357.","journal-title":"Int J Pharm"},{"key":"2097_CR180","doi-asserted-by":"publisher","DOI":"10.1016\/j.hsr.2022.100038","volume":"4","author":"M Handa","year":"2022","unstructured":"Handa M, et al. Potential of particle size less than 15 nm via olfactory region for direct brain delivery via intranasal route. Health Sciences Review. 2022;4:100038.","journal-title":"Health Sciences Review"},{"issue":"1","key":"2097_CR181","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1002\/jemt.1070230105","volume":"23","author":"EE Morrison","year":"1992","unstructured":"Morrison EE, Costanzo RM. Morphology of olfactory epithelium in humans and other vertebrates. Microsc Res Tech. 1992;23(1):49\u201361.","journal-title":"Microsc Res Tech"},{"issue":"3","key":"2097_CR182","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1039\/C6NR07581A","volume":"9","author":"E Ahmad","year":"2017","unstructured":"Ahmad E, et al. Evidence of nose-to-brain delivery of nanoemulsions: cargoes but not vehicles. Nanoscale. 2017;9(3):1174\u201383.","journal-title":"Nanoscale"},{"key":"2097_CR183","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.jconrel.2022.03.017","volume":"344","author":"T Kurano","year":"2022","unstructured":"Kurano T, et al. Nose-to-brain\/spinal cord delivery kinetics of liposomes with different surface properties. J Control Release. 2022;344:225\u201334.","journal-title":"J Control Release"},{"key":"2097_CR184","doi-asserted-by":"publisher","first-page":"5619","DOI":"10.2147\/IJN.S452316","volume":"19","author":"A Bonaccorso","year":"2024","unstructured":"Bonaccorso A, et al. Nose-to-brain drug delivery and physico-chemical properties of nanosystems: analysis and correlation studies of data from scientific literature. Int J Nanomedicine. 2024;19:5619\u201336.","journal-title":"Int J Nanomedicine"},{"key":"2097_CR185","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.jconrel.2021.05.020","volume":"335","author":"E Truzzi","year":"2021","unstructured":"Truzzi E, et al. Nasal biocompatible powder of Geraniol oil complexed with cyclodextrins for neurodegenerative diseases: physicochemical characterization and in vivo evidences of nose to brain delivery. J Control Release. 2021;335:191\u2013202.","journal-title":"J Control Release"},{"key":"2097_CR186","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.jconrel.2021.02.024","volume":"332","author":"M Fukuda","year":"2021","unstructured":"Fukuda M, et al. Quantitative analysis of inulin distribution in the brain focused on nose-to-brain route via olfactory epithelium by reverse esophageal cannulation. J Control Release. 2021;332:493\u2013501.","journal-title":"J Control Release"},{"issue":"4","key":"2097_CR187","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1080\/107175499266823","volume":"6","author":"M Quadir","year":"1999","unstructured":"Quadir M, Zia H, Needham TE. Toxicological implications of nasal formulations. Drug Deliv. 1999;6(4):227\u201342.","journal-title":"Drug Deliv"},{"issue":"5","key":"2097_CR188","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1039\/D4PM00057A","volume":"1","author":"M Das","year":"2024","unstructured":"Das M, et al. Insight into central nervous system targeted nanostructured lipid carriers via the nose to brain pathway. RSC Pharmaceutics. 2024;1(5):904\u201327.","journal-title":"RSC Pharmaceutics"},{"issue":"2","key":"2097_CR189","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/0378-5173(94)00238-Z","volume":"114","author":"CP Pujara","year":"1995","unstructured":"Pujara CP, et al. Effects of formulation variables on nasal epithelial cell integrity: biochemical evaluations. Int J Pharm. 1995;114(2):197\u2013203.","journal-title":"Int J Pharm"},{"issue":"6","key":"2097_CR190","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1046\/j.1365-2273.2000.00420.x","volume":"25","author":"JJ Homer","year":"2000","unstructured":"Homer JJ, et al. The effect of hypertonicity on nasal mucociliary clearance. Clin Otolaryngol Allied Sci. 2000;25(6):558\u201360.","journal-title":"Clin Otolaryngol Allied Sci"},{"key":"2097_CR191","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics16040481","author":"S Gandhi","year":"2024","unstructured":"Gandhi S, et al. Nasal delivery to the brain: harnessing nanoparticles for effective drug transport. Pharmaceutics. 2024. https:\/\/doi.org\/10.3390\/pharmaceutics16040481.","journal-title":"Pharmaceutics"},{"key":"2097_CR192","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.jconrel.2016.04.014","volume":"232","author":"B Bernocchi","year":"2016","unstructured":"Bernocchi B, et al. Mechanisms allowing protein delivery in nasal mucosa using NPL nanoparticles. J Control Release. 2016;232:42\u201350.","journal-title":"J Control Release"},{"issue":"8","key":"2097_CR193","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0255778","volume":"16","author":"KM Pusic","year":"2021","unstructured":"Pusic KM, Kraig RP, Pusic AD. IFN\u03b3-stimulated dendritic cell extracellular vesicles can be nasally administered to the brain and enter oligodendrocytes. PLoS One. 2021;16(8):e0255778.","journal-title":"PLoS One"},{"issue":"1\u20132","key":"2097_CR194","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.ijpharm.2015.12.046","volume":"499","author":"O Gartziandia","year":"2016","unstructured":"Gartziandia O, et al. Nanoparticle transport across in vitro olfactory cell monolayers. Int J Pharm. 2016;499(1\u20132):81\u20139.","journal-title":"Int J Pharm"},{"issue":"2","key":"2097_CR195","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.ejpb.2009.08.008","volume":"74","author":"A Wengst","year":"2010","unstructured":"Wengst A, Reichl S. RPMI 2650 epithelial model and three-dimensional reconstructed human nasal mucosa as in vitro models for nasal permeation studies. Eur J Pharm Biopharm. 2010;74(2):290\u20137.","journal-title":"Eur J Pharm Biopharm"},{"key":"2097_CR196","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11082198","author":"R Boyuklieva","year":"2023","unstructured":"Boyuklieva R, Zagorchev P, Pilicheva B. Computational, in vitro, and in vivo models for nose-to-brain drug delivery studies. Biomedicines. 2023. https:\/\/doi.org\/10.3390\/biomedicines11082198.","journal-title":"Biomedicines"},{"key":"2097_CR197","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.cobme.2017.11.002","volume":"5","author":"BD Gastfriend","year":"2018","unstructured":"Gastfriend BD, Palecek SP, Shusta EV. Modeling the blood-brain barrier: beyond the endothelial cells. Curr Opin Biomed Eng. 2018;5:6\u201312.","journal-title":"Curr Opin Biomed Eng"},{"issue":"4","key":"2097_CR198","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1089\/cmb.2017.0149","volume":"25","author":"J Fan","year":"2018","unstructured":"Fan J, Yang J, Jiang Z. Prediction of central nervous system side effects through drug permeability to blood-brain barrier and recommendation algorithm. J Comput Biol. 2018;25(4):435\u201343.","journal-title":"J Comput Biol"},{"key":"2097_CR199","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.vascn.2019.02.008","volume":"97","author":"DV Gauvin","year":"2019","unstructured":"Gauvin DV, Zimmermann ZJ. FOB vs modified Irwin: what are we doing? J Pharmacol Toxicol Methods. 2019;97:24\u20138.","journal-title":"J Pharmacol Toxicol Methods"},{"key":"2097_CR200","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2024.110205","volume":"262","author":"K Liu","year":"2025","unstructured":"Liu K, et al. Microglia phagocytosis of PNNs mediates PV-positive interneuron dysfunction and associated gamma oscillations in neuroinflammation-induced cognitive impairment in mice. Neuropharmacology. 2025;262:110205.","journal-title":"Neuropharmacology"},{"issue":"2","key":"2097_CR201","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1111\/j.1460-9568.2008.06346.x","volume":"28","author":"SM Fleming","year":"2008","unstructured":"Fleming SM, et al. Olfactory deficits in mice overexpressing human wildtype alpha-synuclein. Eur J Neurosci. 2008;28(2):247\u201356.","journal-title":"Eur J Neurosci"},{"issue":"2\u20133","key":"2097_CR202","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/0306-4522(91)90355-R","volume":"41","author":"F Anton","year":"1991","unstructured":"Anton F, et al. C-FOS-like immunoreactivity in rat brainstem neurons following noxious chemical stimulation of the nasal mucosa. Neuroscience. 1991;41(2\u20133):629\u201341.","journal-title":"Neuroscience"},{"issue":"4 Pt 1","key":"2097_CR203","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1097\/00005537-200104000-00008","volume":"111","author":"P Merkus","year":"2001","unstructured":"Merkus P, et al. Classification of cilio-inhibiting effects of nasal drugs. Laryngoscope. 2001;111(4 Pt 1):595\u2013602.","journal-title":"Laryngoscope"},{"issue":"2","key":"2097_CR204","doi-asserted-by":"publisher","DOI":"10.1002\/wnan.1956","volume":"16","author":"K Xu","year":"2024","unstructured":"Xu K, et al. Nose-to-brain delivery of nanotherapeutics: transport mechanisms and applications. WIREs Nanomed Nanobiotechnol. 2024;16(2):e1956.","journal-title":"WIREs Nanomed Nanobiotechnol"},{"issue":"6","key":"2097_CR205","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.70213","volume":"6","author":"Y Qiu","year":"2025","unstructured":"Qiu Y, et al. The nasal-brain drug delivery route: mechanisms and applications to central nervous system diseases. MedComm. 2025;6(6):e70213.","journal-title":"MedComm"},{"issue":"1","key":"2097_CR206","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0165-0270(02)00033-X","volume":"116","author":"MP van den Berg","year":"2002","unstructured":"van den Berg MP, et al. Serial cerebrospinal fluid sampling in a rat model to study drug uptake from the nasal cavity. J Neurosci Methods. 2002;116(1):99\u2013107.","journal-title":"J Neurosci Methods"},{"issue":"3","key":"2097_CR207","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1080\/01926230600713475","volume":"34","author":"JR Harkema","year":"2006","unstructured":"Harkema JR, Carey SA, Wagner JG. The nose revisited: a brief review of the comparative structure, function, and toxicologic pathology of the nasal epithelium. Toxicol Pathol. 2006;34(3):252\u201369.","journal-title":"Toxicol Pathol"},{"issue":"7","key":"2097_CR208","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1007\/s40263-021-00826-9","volume":"35","author":"RL Doty","year":"2021","unstructured":"Doty RL, et al. Effect of Esketamine Nasal Spray on Olfactory Function and Nasal Tolerability in Patients with Treatment-Resistant Depression: results from four multicenter, randomized, double-blind, placebo-controlled, phase III studies. CNS Drugs. 2021;35(7):781\u201394.","journal-title":"CNS Drugs"},{"issue":"1","key":"2097_CR209","volume":"15","author":"N Niraj","year":"2023","unstructured":"Niraj N, et al. The evaluation of the efficacy and safety of midazolam nasal spray in patients with seizure clusters: a systematic review and meta-analysis. Cureus. 2023;15(1):e34064.","journal-title":"Cureus"},{"issue":"5","key":"2097_CR210","first-page":"1225","volume":"49","author":"R Ryan","year":"1997","unstructured":"Ryan R, et al. Sumatriptan nasal spray for the acute treatment of migraine. Results of two clinical studies Neurology. 1997;49(5):1225\u201330.","journal-title":"Results of two clinical studies Neurology"},{"issue":"6","key":"2097_CR211","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1177\/08971900221108725","volume":"36","author":"KL Zitko","year":"2023","unstructured":"Zitko KL, Ladd L, Dougherty TS. Intranasal Varenicline: review of a novel formulation for the treatment of dry eye disease. J Pharm Pract. 2023;36(6):1448\u201353.","journal-title":"J Pharm Pract"},{"issue":"12","key":"2097_CR212","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1007\/s40263-024-01118-8","volume":"38","author":"SJ Tepper","year":"2024","unstructured":"Tepper SJ, et al. Long-term (12-month) safety and tolerability of STS101 (Dihydroergotamine Nasal Powder) in the acute treatment of migraine: data from the Phase 3 Open-Label ASCEND Study. CNS Drugs. 2024;38(12):1017\u201327.","journal-title":"CNS Drugs"},{"key":"2097_CR213","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2024.1346109","volume":"12","author":"A Dahan","year":"2024","unstructured":"Dahan A, et al. Fact vs. fiction: naloxone in the treatment of opioid-induced respiratory depression in the current era of synthetic opioids. Front Public Health. 2024;12:1346109.","journal-title":"Front Public Health"},{"issue":"1","key":"2097_CR214","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s10194-025-01984-7","volume":"26","author":"Z Zhu","year":"2025","unstructured":"Zhu Z, et al. The efficacy and safety of zavegepant nasal inhalation versus oral calcitonin-gene related peptide receptor antagonists in the acute treatment of migraine: a systematic review and network meta-analysis of the literature. J Headache Pain. 2025;26(1):48.","journal-title":"J Headache Pain"},{"issue":"1","key":"2097_CR215","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s12954-022-00627-3","volume":"19","author":"R Abdelal","year":"2022","unstructured":"Abdelal R, et al. Real-world study of multiple naloxone administration for opioid overdose reversal among bystanders. Harm Reduct J. 2022;19(1):49.","journal-title":"Harm Reduct J"},{"key":"2097_CR216","volume-title":"Essential drug delivery outputs for devices intended to deliver drugs and biological products","year":"2024","unstructured":"USFDA. Essential drug delivery outputs for devices intended to deliver drugs and biological products, USFDA, Editor. U.S. Department of Health and Human Services: Rockville, MD; 2024."},{"key":"2097_CR217","volume-title":"HHS-0910\u20132002-F-5013","author":"USFDA","year":"2002","unstructured":"USFDA. Nasal spray and inhalation solution, suspension, and spray drug products--chemistry, manufacturing, and controls documentation: guidance for industry, in HHS-0910\u20132002-F-5013, USFDA, Editor. U.S. Department of Health and Human Services, Center for Drug Evaluation and Research (CDER): Rockville, MD; 2002."},{"key":"2097_CR218","volume-title":"EMEA\/CHMP\/ QWP\/49313\/2005","author":"EMA","year":"2006","unstructured":"EMA. Guideline on the pharmaceutical quality of inhalation and nasal products - First version. In: EMEA\/CHMP\/ QWP\/49313\/2005. The Netherlands: E.M. Agency; 2006."},{"key":"2097_CR219","volume-title":"EMEA\/CHMP\/QWP\/49313\/2005 Rev. 1","author":"EMA","year":"2026","unstructured":"EMA. Guideline on the pharmaceutical quality of inhalation and nasal products - First version. In: EMEA\/CHMP\/QWP\/49313\/2005 Rev. 1. The Netherlands: E.M. Agency; 2026."},{"key":"2097_CR220","volume-title":"FDA-1999-D-0050","author":"USFDA","year":"2003","unstructured":"USFDA. Bioavailability and bioequivalence studies for nasal aerosols and nasal sprays for local action. In: Cder F, editor. FDA-1999-D-0050. Rockville, MD: U.S. Department of Health and Human Services; 2003."},{"key":"2097_CR221","doi-asserted-by":"publisher","DOI":"10.3389\/fvets.2023.1172140","volume":"10","author":"J Xi","year":"2023","unstructured":"Xi J, Si XA, Malve M. Nasal anatomy and sniffing in respiration and olfaction of wild and domestic animals. Front Vet Sci. 2023;10:1172140.","journal-title":"Front Vet Sci"},{"key":"2097_CR222","doi-asserted-by":"crossref","unstructured":"Rigaut C, et al. Instillation of a dry powder in nasal casts: parameters influencing the olfactory deposition with uni- and bi-directional devices. Front Med Technol. 2022;4.","DOI":"10.3389\/fmedt.2022.924501"},{"key":"2097_CR223","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15122661","author":"C Rigaut","year":"2023","unstructured":"Rigaut C, et al. What are the key anatomical features for the success of nose-to-brain delivery? A study of powder deposition in 3D-printed nasal casts. Pharmaceutics. 2023. https:\/\/doi.org\/10.3390\/pharmaceutics15122661.","journal-title":"Pharmaceutics"},{"issue":"6","key":"2097_CR224","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1208\/s12249-022-02351-4","volume":"23","author":"I-M Menegatou","year":"2022","unstructured":"Menegatou I-M, et al. Design of a personalized nasal device (Matrix-Piston Nasal Device, MPD) for drug delivery: a 3D-printing application. AAPS PharmSciTech. 2022;23(6):205.","journal-title":"AAPS PharmSciTech"},{"key":"2097_CR225","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.ijpharm.2019.02.026","volume":"561","author":"L Salade","year":"2019","unstructured":"Salade L, et al. How to characterize a nasal product. The state of the art of in vitro and ex vivo specific methods. Int J Pharm. 2019;561:47\u201365.","journal-title":"Int J Pharm"},{"key":"2097_CR226","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.addr.2020.09.002","volume":"170","author":"S Le Guellec","year":"2021","unstructured":"Le Guellec S, Ehrmann S, Vecellio L. In vitro - in vivo correlation of intranasal drug deposition. Adv Drug Deliv Rev. 2021;170:340\u201352.","journal-title":"Adv Drug Deliv Rev"},{"key":"2097_CR227","unstructured":"Abstracts from the aerosol society drug delivery to the lungs 34. Journal of Aerosol Medicine and Pulmonary Drug Delivery. 2024."},{"key":"2097_CR228","first-page":"36","volume-title":"ONdrugDelivery","author":"S Conte","year":"2025","unstructured":"Conte S, Regard A. Nose-to-Brain Delivery: Patient-Centric Device Development and Performance Testing. In: ONdrugDelivery. United Kingdom: Furness Publishing Ltd; 2025. p. 36\u20139."},{"issue":"2","key":"2097_CR229","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1080\/1061186X.2017.1350858","volume":"26","author":"V Sridhar","year":"2018","unstructured":"Sridhar V, et al. Brain targeted delivery of mucoadhesive thermosensitive nasal gel of selegiline hydrochloride for treatment of Parkinson\u2019s disease. J Drug Target. 2018;26(2):150\u201361.","journal-title":"J Drug Target"},{"issue":"10","key":"2097_CR230","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1080\/03639045.2018.1483387","volume":"44","author":"S Salatin","year":"2018","unstructured":"Salatin S, et al. Box\u2013Behnken experimental design for preparation and optimization of the intranasal gels of selegiline hydrochloride. Drug Dev Ind Pharm. 2018;44(10):1613\u201321.","journal-title":"Drug Dev Ind Pharm"},{"issue":"1","key":"2097_CR231","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1080\/03639045.2016.1225754","volume":"43","author":"M Rao","year":"2017","unstructured":"Rao M, Agrawal DK, Shirsath C. Thermoreversible mucoadhesive in situ nasal gel for treatment of Parkinson\u2019s disease. Drug Dev Ind Pharm. 2017;43(1):142\u201350.","journal-title":"Drug Dev Ind Pharm"},{"issue":"1","key":"2097_CR232","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.ijpharm.2014.04.015","volume":"468","author":"S Qian","year":"2014","unstructured":"Qian S, Wong YC, Zuo Z. Development, characterization and application of in situ gel systems for intranasal delivery of tacrine. Int J Pharm. 2014;468(1):272\u201382.","journal-title":"Int J Pharm"},{"issue":"11","key":"2097_CR233","first-page":"1480","volume":"29","author":"M Hidestrand","year":"2001","unstructured":"Hidestrand M, et al. CYP2B6 and CYP2C19 as the major enzymes responsible for the metabolism of selegiline, a drug used in the treatment of Parkinson\u2019s disease, as revealed from experiments with recombinant enzymes. Drug Metab Dispos. 2001;29(11):1480\u20134.","journal-title":"Drug Metab Dispos"},{"issue":"12","key":"2097_CR234","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.2174\/156802608785161457","volume":"8","author":"K Trond","year":"2008","unstructured":"Trond K, John H, Ingebrigt S. Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049\u201367.","journal-title":"Curr Top Med Chem"},{"key":"2097_CR235","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.actbio.2023.09.038","volume":"171","author":"L Liu","year":"2023","unstructured":"Liu L, et al. Stimuli-responsive nanoparticles delivered by a nasal-brain pathway alleviate depression-like behavior through extensively scavenging ROS. Acta Biomater. 2023;171:451\u201365.","journal-title":"Acta Biomater"},{"issue":"6","key":"2097_CR236","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1111\/jphp.12043","volume":"65","author":"X Chen","year":"2013","unstructured":"Chen X, et al. Enhanced brain targeting of curcumin by intranasal administration of a thermosensitive poloxamer hydrogel. J Pharm Pharmacol. 2013;65(6):807\u201316.","journal-title":"J Pharm Pharmacol"},{"issue":"7","key":"2097_CR237","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1208\/s12249-019-1513-x","volume":"20","author":"Y Chen","year":"2019","unstructured":"Chen Y, et al. A nasal temperature and pH dual-responsive in situ gel delivery system based on microemulsion of Huperzine A: formulation, evaluation, and in vivo pharmacokinetic study. AAPS PharmSciTech. 2019;20(7):301.","journal-title":"AAPS PharmSciTech"},{"key":"2097_CR238","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ijbiomac.2016.02.044","volume":"87","author":"SR Salunke","year":"2016","unstructured":"Salunke SR, Patil SB. Ion activated in situ gel of gellan gum containing salbutamol sulphate for nasal administration. Int J Biol Macromol. 2016;87:41\u20137.","journal-title":"Int J Biol Macromol"},{"issue":"8","key":"2097_CR239","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1080\/10837450.2021.1948571","volume":"26","author":"S Taymouri","year":"2021","unstructured":"Taymouri S, et al. In vitro and in\u00a0vivo evaluation of an ionic sensitive in situ gel containing nanotransfersomes for aripiprazole nasal delivery. Pharm Dev Technol. 2021;26(8):867\u201379.","journal-title":"Pharm Dev Technol"},{"key":"2097_CR240","unstructured":"Davitian M, et al. CNS year in review: introduction and large CNS diseases, Health advances LLC 2025. Newton, MA; 2023a. https:\/\/www.healthadvances.com\/insights\/blog\/cns-year-in-review-introduction-and-large-cns-diseases."},{"key":"2097_CR241","unstructured":"Davitian M, et al. CNS year in review: going digital. In: Health advances LLC 2025. Newton, MA; 2023b. https:\/\/www.healthadvances.com\/insights\/blog\/cns-year-inreview-going-digital."},{"issue":"3","key":"2097_CR242","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1177\/2168479017725556","volume":"52","author":"VL Anthony Berauk","year":"2018","unstructured":"Anthony Berauk VL, et al. Mobile health applications for caring of older people: review and comparison. Therapeutic Innovation & Regulatory Science. 2018;52(3):374\u201382.","journal-title":"Therapeutic Innovation & Regulatory Science"},{"issue":"7","key":"2097_CR243","first-page":"347","volume":"39","author":"SH Tak","year":"2021","unstructured":"Tak SH. In quest of tablet apps for elders with Alzheimer\u2019s disease: a descriptive review. Comput Inform Nurs. 2021;39(7):347\u201354.","journal-title":"Comput Inform Nurs"},{"key":"2097_CR244","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13020403","author":"Z Biskupiak","year":"2024","unstructured":"Biskupiak Z, et al. Digital therapeutics for improving effectiveness of pharmaceutical drugs and biological products: preclinical and clinical studies supporting development of drug + digital combination therapies for chronic diseases. J Clin Med. 2024. https:\/\/doi.org\/10.3390\/jcm13020403.","journal-title":"J Clin Med"},{"key":"2097_CR245","unstructured":"Botha M, Bilstein A, Elghobary H. A game changer for high-risk medications via intranasal drug delivery platform. ONDrugDelivery. 2022;38\u201344."}],"container-title":["Drug Delivery and Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-026-02097-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13346-026-02097-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-026-02097-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T14:02:55Z","timestamp":1783519375000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13346-026-02097-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,21]]},"references-count":245,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["2097"],"URL":"https:\/\/doi.org\/10.1007\/s13346-026-02097-7","relation":{},"ISSN":["2190-393X","2190-3948"],"issn-type":[{"value":"2190-393X","type":"print"},{"value":"2190-3948","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,21]]},"assertion":[{"value":"5 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}},{"value":"B.S. Bleier has consultant relationships with Olympus, Karl Storz, Medtronic, Sound Health Systems Inc., Stryker, 3D Matrix, Diceros Rx and receives royalties from Thieme. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"During the preparation of this work, the author(s) utilized ChatGPT to enhance language and readability.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"AI disclosure"}}]}}